Mylan Collaborated with Atomo Diagnostics for Commercialization of HIV Rapid Diagnostic tests for Low and Middle-Income Countries

 Mylan Collaborated with Atomo Diagnostics for Commercialization of HIV Rapid Diagnostic tests for Low and Middle-Income Countries

Mylan Collaborated with Atomo Diagnostics for Commercialization of HIV Rapid Diagnostic tests for Low and Middle-Income Countries

Shots:

  • Mylan to get exclusive commercialization rights of the product in >100 countries, including Africa, Asia, the Middle East, the Commonwealth of Independent States (CIS) and Latin America. Mylan plans to launch Mylan HIV Self-Test in global markets in 2019
  • CE-Marked in-vitro HIV rapid diagnostic tests allow individuals to detect presence or absence of HIV Abs in a single drop of blood obtained from fingertip demonstrating the results in fifteen minutes
  • Out of 36.7M population one-third are still undiagnosed and unaware of HIV infection. The tests will allow individuals to self-check in the privacy with simple and accurate device

Click here to read full press release/ article | Ref: Atomo Diagnostics | Image: Helmsleyrashid

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post